Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APP13007 Phase 3 for Inflammation and Pain After Cataract Surgery
NCT04739709Phase 3Completed
- Sponsor
- Formosa Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- Mar 2022
- Modality
- Nanoparticles, Implantable Devices, Hydrogel Systems
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in post-operative ocular inflammation and post-operative ocular pain comparing APP13007 with Placebo (2 arms). Primary endpoints: Participants With ACC Count = 0 at All Visits From Postoperative Day 8 Through Postoperative Day 15 Without Rescue Medication, Participants With Ocular Pain Grade = 0 at All Visits From Postoperative Day 4 Through Postoperative Day 15 Without Rescue Medication and 1 more. Started Jan 2021; status: completed.
02
Drugs
GPN00833
03
Conditions
post-operative ocular inflammationpost-operative ocular pain
Beyond the preview
Go deeper on NCT04739709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04739709.